Acquisition ImpactThe NeoOrtho acquisition makes sense as many markets struggle with care affordability, offering a way to differentiate the premium Swiss brand while gaining access to volume and scale that large tenders offer.

Growth ExpectationsFY25 guide looks achievable with a 13%-15% organic Sales growth outlook and a more robust EBITDA range in the high-teens guided for FY25.

Product StrategyMore focus on Upper Extremities going forward, where the portfolio is complete, and the Keri Touch thumb device can generate pull-through, is seen as the right approach.

Bears Say

Market GuidanceTop-line FY25 guidance is approximately 7-9% below consensus, which is causing disappointment despite EBITDA being in line.

Operational IssuesManagement referred to issues surrounding client engagement/onboarding, set retrieval/line filling, and management changes and unachievable targets in the U.S.

US Market ChallengesThe US market is undergoing a strategic review, with 2024 being a transition year, and growth in this region is key to future success.

Financials

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

―

Insiders

1.11%

Mutual Funds

― Other Institutional Investors

97.95% Public Companies and

Individual Investors

Detailed Ownership Overview >

MED FAQ

What was Medartis Holding AG’s price range in the past 12 months?

Medartis Holding AG lowest stock price was CHF44.15 and its highest was CHF89.10 in the past 12 months.

What is Medartis Holding AG’s market cap?

Medartis Holding AG’s market cap is CHF1.17B.

When is Medartis Holding AG’s upcoming earnings report date?

Medartis Holding AG’s upcoming earnings report date is Aug 19, 2025 which is in 21 days.

How were Medartis Holding AG’s earnings last quarter?

Medartis Holding AG released its earnings results on Mar 18, 2025. The company reported CHF0.078 earnings per share for the quarter, beating the consensus estimate of N/A by CHF0.078.

Is Medartis Holding AG overvalued?

According to Wall Street analysts Medartis Holding AG’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Medartis Holding AG pay dividends?

Medartis Holding AG does not currently pay dividends.

What is Medartis Holding AG’s EPS estimate?

Medartis Holding AG’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Medartis Holding AG have?

Medartis Holding AG has 13,618,027 shares outstanding.

What happened to Medartis Holding AG’s price movement after its last earnings report?

Medartis Holding AG reported an EPS of CHF0.078 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 3.262%.

Which hedge fund is a major shareholder of Medartis Holding AG?

Currently, no hedge funds are holding shares in CH:MED

Company Description

Medartis Holding AG

Medartis Holding AG, a medical device company, develops, manufactures, and sells implant solutions worldwide. Its medical devices are used for the treatment of surgical fixation of bone fractures for upper and lower extremities, as well as for the cranio-maxillofacial surgery. The company offers osteosynthesis instruments for the areas of the hand, wrist, elbow, shoulder, and foot and ankle, as well as for the areas of the mandible, midface, orthognathic, and cranium under the APTUS and MODUS names. The company serves the surgeons, hospitals, and medical centers, as well as group purchasing organizations. Medartis Holding AG was founded in 1997 and is headquartered in Basel, Switzerland.